Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model. - Wikidata - awgldk - TriplyDB

Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model.

Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model.

http://www.wikidata.org/entity/Q35465768

about

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model.

P2860

Q30397031-BFD29770-2731-4045-AFAF-42B55F540D23 Q55114408-1DDE5613-83C9-4857-B327-16E92940AA39

P2860

Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model.

http://www.wikidata.org/entity/Q35465768

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Evaluation of Immunostimulator ...... tro Human Immune System Model.

@ast

Evaluation of Immunostimulator ...... tro Human Immune System Model.

@en

type

label

Evaluation of Immunostimulator ...... tro Human Immune System Model.

@ast

Evaluation of Immunostimulator ...... tro Human Immune System Model.

@en

prefLabel

Evaluation of Immunostimulator ...... tro Human Immune System Model.

@ast

Evaluation of Immunostimulator ...... tro Human Immune System Model.

@en

P1433

Q35465768-20CBBAF5-8C95-41C6-834E-5949F2820D50

P1476

Q35465768-27B2F915-3B18-4A5E-97BB-11F5E829BACA

P2093

Q35465768-08B52BB6-F933-48C5-B1D1-822771D31A35

Q35465768-169E316D-3416-4924-9E44-D3DF8E6356FB

Q35465768-404A3673-A33F-44F2-A415-5A392AE3B7E8

Q35465768-6E8E68AD-1D38-4983-B140-B2637C4A18AE

Q35465768-72F8B980-F270-4113-82F4-FA7EC50E8DBD

Q35465768-77FF6CE4-6A32-42F5-99CD-0BA4E915C556

Q35465768-A7AB02A0-6006-4EEF-950D-4702609E13E0

Q35465768-D2B8D5CD-D087-47D6-8D5C-9FE567DE6DDF

P2860

Q35465768-00389AC1-04F3-421D-A438-0E8E46009862

Q35465768-11B25E4A-E5BA-47D6-B592-B7EBDB144A60

Q35465768-294308CE-B0D2-4D45-9552-DB72CEAD9422

Q35465768-3A3AFFA2-4B1F-47DE-A06B-19EC75D1C0F5

Q35465768-4064CCA8-4252-49EB-8E47-5A34E1BD7D63

Q35465768-5B99B7B1-3847-47FF-873C-ACC986D8B4A8

Q35465768-6ABD7C34-3CB3-4DD5-AA3A-5E766DC45E2C

Q35465768-7D7A8DDB-79BE-4AD1-B6F6-821751B3D3B4

Q35465768-80FD4CC0-613B-4861-98E0-2092A7956E3F

Q35465768-8D690F8D-4500-4429-8173-24FF83E501A0

P304

Q35465768-C1B76C81-2407-467A-A1FC-C0786DF8C0E8

P31

Q35465768-4A9FCE8E-B1D7-466F-AE5A-5920DE5E200F

P356

Q35465768-370732A0-E63F-4425-8615-B21CF8CF5F06

P433

Q35465768-06FCC2F2-D6EF-4EBC-B575-C99995283908

P478

Q35465768-993AF1DE-E9BB-4F41-876F-DAC6B9AB1093

P577

Q35465768-055FDDC1-3F1C-4C0D-8B13-C351DB389AE8

P5875

Q35465768-2EC1B7FC-77CE-4128-BDB6-0DA681AF3A23

P698

Q35465768-03DC7563-D11D-4593-A0FB-AFB3920BDCB1

P932

Q35465768-89AFEA4E-0DDF-429F-834E-DE6CAF404ACE

P356

1076029614562037

P1433

Clinical and Applied Thrombosis-Hemostasis

P1476

Evaluation of Immunostimulator ...... tro Human Immune System Model.

@en

P2093

Charlotte Vernhes

http://www.w3.org/2001/XMLSchema#string

Christian Viskov

http://www.w3.org/2001/XMLSchema#string

Donald R Drake

http://www.w3.org/2001/XMLSchema#string

Ernesto Luna

http://www.w3.org/2001/XMLSchema#string

Jean Amiral

http://www.w3.org/2001/XMLSchema#string

Pankaj Agrawal

http://www.w3.org/2001/XMLSchema#string

Riyaz Mehta

http://www.w3.org/2001/XMLSchema#string

William L Warren

http://www.w3.org/2001/XMLSchema#string

P2860

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells

Expression of tissue factor and tissue factor pathway inhibitor in rats lungs with lipopolysaccharide-induced disseminated intravascular coagulation

Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs.

Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.

Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.

Determinants of PF4/heparin immunogenicity

Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.

Optimization of a murine immunization model for study of PF4/heparin antibodies.

Heparin modifies the immunogenicity of positively charged proteins.

Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay.

P304

211-222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1076029614562037

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269765398

http://www.w3.org/2001/XMLSchema#string

P698

25525049

http://www.w3.org/2001/XMLSchema#string

P932

4401814

http://www.w3.org/2001/XMLSchema#string